The latest biotech news

News and Trends 29 Jun 2015

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Actelion has created a new start-up in the field of synthetic carbohydrate vaccines, together with the Max Planck Society. Actelion has made a funding commitment of up to €30M to back the new company, Vaxxilon. Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces discovered the first preclinical […]

June 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 29 Jun 2015

Novartis pays €625M for Spinifex’s chronic pain treatment

[Update 06.30.2015] According to an email sent to FierceBiotech by Spinifex’s CEO Tom McCarthy, Novartis could pay an additional $500m (approximately €445m) of future milestones to Spinifex’s shareholders. Spinifex Pharmaceuticals, a US-Australian biotechnology company has just been bought by Novartis. With this acquisition, the Swiss giant aims to control the development of EMA401, a new treatment for […]

June 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 Jun 2015

6 Things the Digital Revolution already Disrupted in the Biotech Industry

2 weeks ago, I was at NOAH15 in Berlin, one of the biggest European events on Digital, gathering key opinion leaders such as Eric Schmidt from Google or Ariana Huffington, founder of the Huffington Post. They all talked about the impact of the recent digital wave, internet and the post-pc area in different industries. Biotech […]

June 29, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 28 Jun 2015

Google and big names helped Oxford Sciences Innovation to raise €457M

Oxford Sciences Innovation has completed the second close of its fundraising, raising an additional €157.3M (£110M) and bringing the total amount raised to €457.6M (£320M). This second close included some well-known investors such as Google Ventures and Charles Dunstone. Being backed by one of the best-recognized institutions in the world has its advantages. Oxford University […]

June 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

AstraZeneca’s senior managers are abandoning ship

In just a couple of weeks, AstraZeneca has seen two of its chiefs leave their position to run two smaller biotechs. James Ward-Lilley made his exist from Astra to become CEO of Vectura, just a few days after Briggs Morrison abruptly left to also become CEO of Syndax. The rich also cry, said the telenovela and […]

June 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 25 Jun 2015

A treatment for Spinal Muscular Atrophy received Orphan Drug designation

The European Medicines Agency has granted Orphan Drug designation to AveXis’ gene transfer candidate. The therapy is currently in clinical development in the United States for the treatment of type 1 Spinal Muscular Atrophy and already received Orphan Drug designation for this disease in the United States. Spinal Muscular Atrophy is an autosomal-recessive genetic disorder […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 24 Jun 2015

AYOXXA and Grünenthal collaborate on inflammation markers

AYOXXA Biosystems and Grünenthal have completed their first research collaboration to validate detection limits for a biomarker based on AYOXXA’s platform. The outcomes of this collaboration can be applied in several fields that include biological samples with very low initial volume, previously inaccessible by other immunoassays. The focus of the joint study consisted in analyzing […]

June 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

DBV Technologies to cure Peanut allergy

DBV Technologies plans the initiation of its phase III clinical trial for Viaskin Peanut, after a satisfactory conclusion of the phase II. The drug candidate already achieved a positive opinion from the Paediatric Committee of the European Medicines Agency. Both FDA and EMA desire to move forward with the development of what may be the […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

Chris Viehbacher to run Swiss billionaire’s investment fund

One of our favorite bio-celebrities is enlarging his CV with a new job position. The German-Canadian Chris Viehbacher will run the billionaire Gurnet Point Capital fund, owned by the Swiss magnate Ernesto Bertarelli. If Chris Viehbacher felt disappointed after being dumped from Sanofi, at least he didn’t lose his pharma thrill. Recently, however, the business […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

Will Boehringer Ingelheim win the race for anticoagulants?

Boehringer Ingelheim has released the last figures of its idarucizumab Phase III. The breakthrough anti-anticoagulant is being studied as an antidote to Boehringer’s blockbuster Pradaxa. Pradaxa was the first widely approved drug in a new generation of direct oral anticoagulants, a blockbuster developed by Boehringer Ingelheim. However, there is no specific antidote available yet to […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Novartis pays €625M for Spinifex’s chronic pain treatment

6 Things the Digital Revolution already Disrupted in the Biotech Industry

Google and big names helped Oxford Sciences Innovation to raise €457M

AstraZeneca’s senior managers are abandoning ship

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Video: Discover How CAR-T Therapies are Working

A treatment for Spinal Muscular Atrophy received Orphan Drug designation

AYOXXA and Grünenthal collaborate on inflammation markers

DBV Technologies to cure Peanut allergy

Chris Viehbacher to run Swiss billionaire’s investment fund

Will Boehringer Ingelheim win the race for anticoagulants?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!